{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:58:18Z","timestamp":1792475898101,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,11,28]],"date-time":"2007-11-28T00:00:00Z","timestamp":1196208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1245\/s10434-007-9699-7","type":"journal-article","created":{"date-parts":[[2007,11,27]],"date-time":"2007-11-27T21:06:10Z","timestamp":1196197570000},"page":"738-744","source":"Crossref","is-referenced-by-count":51,"title":["VEGF Expression Predicts Survival in Patients with Peritoneal Surface Metastases from Mucinous Adenocarcinoma of the Appendix and Colon"],"prefix":"10.1245","volume":"15","author":[{"given":"Jocelyn M.","family":"Logan-Collins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni M.","family":"Robinson-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seena","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Sussman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,11,28]]},"reference":[{"key":"9699_CR1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00000658-197311000-00006","volume":"178","author":"GK Limber","year":"1973","unstructured":"Limber GK, King RE, Silverberg SG. Pseudomyxoma peritonaei: a report of ten cases. Ann Surg 1973; 178:587\u201393","journal-title":"Ann Surg"},{"key":"9699_CR2","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/1097-0142(19901001)66:7<1636::AID-CNCR2820660731>3.0.CO;2-N","volume":"66","author":"WJ Mann Jr","year":"1990","unstructured":"Mann WJ Jr, Wagner J, Chumas J, Chalas E. The management of pseudomyxoma peritonei. Cancer 1990; 66:1636\u201340","journal-title":"Cancer"},{"key":"9699_CR3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/01.sla.0000133183.15705.71","volume":"240","author":"O Glehen","year":"2004","unstructured":"Glehen O, Mohamed F, Sugarbaker PH. Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy. Ann Surg 2004; 240:278\u201385","journal-title":"Ann Surg"},{"key":"9699_CR4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00000658-199402000-00002","volume":"219","author":"DB Gough","year":"1994","unstructured":"Gough DB, Donohue JH, Schutt AJ, et al. Pseudomyxoma peritonei. long-term patient survival with an aggressive regional approach. Ann Surg 1994; 219:112\u20139","journal-title":"Ann Surg"},{"key":"9699_CR5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10434-999-0727-7","volume":"6","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999; 6:727\u201331","journal-title":"Ann Surg Oncol"},{"key":"9699_CR6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/ejso.2000.1038","volume":"27","author":"PH Sugarbaker","year":"2001","unstructured":"Sugarbaker PH. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 2001; 27:239\u201343","journal-title":"Eur J Surg Oncol"},{"key":"9699_CR7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","volume":"7","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006; 7:69\u201376","journal-title":"Lancet Oncol"},{"key":"9699_CR8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/01.sla.0000152015.76731.1f","volume":"241","author":"TJ Miner","year":"2005","unstructured":"Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg 2005; 241:300\u20138","journal-title":"Ann Surg"},{"key":"9699_CR9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10434-001-0787-9","volume":"8","author":"AT Culliford","year":"2001","unstructured":"Culliford AT,4th, Brooks AD, Sharma S, et al. Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer. Ann Surg Oncol 2001; 8:787\u201395","journal-title":"Ann Surg Oncol"},{"key":"9699_CR10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1046\/j.1365-2168.2001.01701.x","volume":"88","author":"AJ Witkamp","year":"2001","unstructured":"Witkamp AJ, de Bree E, Kaag MM, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei. Br J Surg 2001; 88:458\u201363","journal-title":"Br J Surg"},{"key":"9699_CR11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1245\/ASO.2004.07.002","volume":"11","author":"M Deraco","year":"2004","unstructured":"Deraco M, Baratti D, Inglese MG, et al. Peritonectomy and intraperitoneal hyperthermic perfusion (IPHP): a strategy that has confirmed its efficacy in patients with pseudomyxoma peritonei. Ann Surg Oncol 2004; 11:393\u20138","journal-title":"Ann Surg Oncol"},{"key":"9699_CR12","first-page":"3964","volume":"55","author":"Y Takahashi","year":"1995","unstructured":"Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964\u20138","journal-title":"Cancer Res"},{"key":"9699_CR13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1001\/archsurg.1997.01430290087018","volume":"132","author":"Y Takahashi","year":"1997","unstructured":"Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132:541\u20136","journal-title":"Arch Surg"},{"key":"9699_CR14","first-page":"221","volume":"18","author":"RM Shaheen","year":"2001","unstructured":"Shaheen RM, Tseng WW, Vellagas R, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 2001; 18:221\u20136","journal-title":"Int J Oncol"},{"key":"9699_CR15","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335\u201342","journal-title":"N Engl J Med"},{"key":"9699_CR16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/000313480006600607","volume":"66","author":"BW Loggie","year":"2000","unstructured":"Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 2000; 66:561\u20138","journal-title":"Am Surg"},{"key":"9699_CR17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1245\/ASO.2004.09.007","volume":"11","author":"SA Ahmad","year":"2004","unstructured":"Ahmad SA, Kim J, Sussman JJ, et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 2004; 11:387\u201392","journal-title":"Ann Surg Oncol"},{"key":"9699_CR18","first-page":"1255","volume":"61","author":"SA Ahmad","year":"2001","unstructured":"Ahmad SA, Liu W, Jung YD, et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001; 61:1255\u20139","journal-title":"Cancer Res"},{"key":"9699_CR19","first-page":"429","volume":"4","author":"Y Takahashi","year":"1998","unstructured":"Takahashi Y, Bucana CD, Akagi Y, et al. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 1998; 4:429\u201334","journal-title":"Clin Cancer Res"},{"key":"9699_CR20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","volume":"6","author":"BK Zebrowski","year":"1999","unstructured":"Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 1999; 6:373\u20138","journal-title":"Ann Surg Oncol"},{"key":"9699_CR21","first-page":"3849","volume":"26","author":"T Yoshikawa","year":"2006","unstructured":"Yoshikawa T, Tsuburaya A, Miyagi Y, et al. Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer. Anticancer Res 2006; 26:3849\u201353","journal-title":"Anticancer Res"},{"key":"9699_CR22","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.humpath.2006.04.031","volume":"37","author":"R Osada","year":"2006","unstructured":"Osada R, Horiuchi A, Kikuchi N, et al. Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Hum Pathol 2006; 37:1414\u201325","journal-title":"Hum Pathol"},{"key":"9699_CR23","first-page":"3001","volume":"23","author":"A Gadducci","year":"2003","unstructured":"Gadducci A, Viacava P, Cosio S, et al. Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res 2003; 23:3001\u20138","journal-title":"Anticancer Res"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-007-9699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-007-9699-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-007-9699-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:10:02Z","timestamp":1684109402000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-007-9699-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,28]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["9699"],"URL":"https:\/\/doi.org\/10.1245\/s10434-007-9699-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,28]]}}}